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Introduction {#sec006}
============

Cancer is a prominent cause of mortality in both economically developed and underdeveloped nations. Unfortunately, the burden is expected to grow globally due to the development and aging of the population, predominantly in less developed countries, where nearly 82% of the world's population resides. Cancer has been found to increase with adoption of life style behaviors like poor dietary habit, sedentary life style, smoking, and reproductive characteristics including having low number of birth, first birth at older age, etc., have further increased the cancer burden in less economically developed countries \[[@pone.0230625.ref001]\]. Cancer was regarded as a problem of affluent societies in the past, however the recent report from GLOBOCAN incidence estimates indicates that greater than 50% of all new cancer cases occur in third world countries (2,561,666 cases compared with 2,175,974 cases in the more developed world)\[[@pone.0230625.ref002]\].

Gynecological cancer, which includes cancers of the cervix, ovary, uterus, vulva, vagina and fallopian tube are among the leading causes of cancer-related mortality worldwide and the distribution and frequency vary across regions. These cancers account for about 10% of all cancers diagnosed in women. The proportion of female genital cancers range from 31.6--35.0% in sub-Saharan Africa to 12.7--13.4% in North America \[[@pone.0230625.ref002], [@pone.0230625.ref003]\]. In 2000, 57,000 of gynecologic cancer cases were reported from sub-Saharan Africa which accounts for 22% of all female cancers corresponding to an age-adjusted incidence of 31/100,000. The disease is among the major causes of cancer related mortality in the continent which is mainly due to late presentation and poor access to diagnosis and treatment \[[@pone.0230625.ref004], [@pone.0230625.ref005]\]. In the year 2010, Ethiopia had a projected population of 20.9 million women aged 15 years and older who were at risk of developing cervical cancer. In the same year, the age-specific incidence of cervical cancer in Ethiopia was higher than the world average for women ages 55 and above. According to a recent WHO report, cervical cancer ranks as the second most common cancer among women in Ethiopia\[[@pone.0230625.ref006]\].

Although gynecologic cancers are an important public health problem, as discussed above, breast cancer is the most common malignancy in women accounting for more than 1/5^th^ of the global burden of cancers worldwide. In 1990s, a 33% increment of breast cancer cases was observed which accounts for more than a million new cases in recorded in 2000. In less developed world, it is the first leading cause of mortality among women accounting for 324,000 deaths that represents more than 14% of all deaths \[[@pone.0230625.ref007]\]. In Ethiopia breast cancer was the most common malignancy accounting for 1/3^rd^ of the cancers in women \[[@pone.0230625.ref008]\].

Information about cancer related deaths and estimation of new/existing number of cancer cases are the most important epidemiological actions that are mandatory to design appropriate cancer control activities and inform the design of national health programs. Cancer incidence estimation was conducted in Ethiopia using population based cancer registry data characterizing recent trends (i.e. 2012--2015) for the most common types of cancer \[[@pone.0230625.ref008]\]. Our study will supplement this existing information by indicating how the incidence of cancer is changing over a longer and more updated time period (i.e. 2014--2018), and providing more detailed information including histological characterization of tumors. Once the varied epidemiological profiles of female cancers in our population are characterized, this information can guide policy makers in determining necessary cancer control measures. To fill the existing information gap, we have used Saint Paul's Hospital Millennium Medical College (SPHMMC)'s oncology unit data to characterize breast and gynecologic malignancies.

Methods {#sec007}
=======

We conducted a retrospective review of Oncology unit records of patients diagnosed to have either breast or any of the gynecological malignancies between January 2014 and December 2018.

SPHMMC is located in Addis Ababa, the capital city of Ethiopia. It is a teaching and referral Hospital located in the western part of Addis Ababa. It is the second hospital offering cancer treatment in the country. All patients who were seen for suspicion of cancer or who were diagnosed with cancer at the Oncology unit and who registered with full information including age, marital status, place of residence, diagnosis in the registration book or in the chart were considered to be eligible for the study.

The following information was collected from the medical record: age, marital status, residence, stage at diagnosis, and cancer histopathological type. Histologic diagnosis was conducted by the Oncology unit of the hospital. The data was analyzed using SPSS version 25.0 (SPSS Inc., Chicago, IL, USA). Frequency distributions of socio-demographic and tumor characteristics of study participants were generated. Linear regression was conducted to identify whether the increase in number of new cases over years is statistically significant and P\<0.05 was considered the threshold for statistical significance.

This study was approved by the SPHMMC Institutional review Board. An official letter of permission was obtained from the Hospital to access the data from the record of patients. The obtained information was kept confidential and only be used for research purpose.

Result {#sec008}
======

The total number of female patients who visited the Oncology unit of SPHMMC over the five year period from 2014--2018 with the suspicion of cancer was 9,261. Five thousand three hundred forty five of these patients were found to have either a malignant or benign tumor, with 2,002 (37.5%) of them being malignant.

Of the total number of cancer cases (n = 2,002), the majority of patients were within the age range of 35--39 and 45--49 accounting for 311 (15.5%) and 265 (13.2%) cases, respectively. The mean and median ages of all the patients were 47.05 ± 13.5 and 46, respectively. The vast majority of the patients were married (\>90%).

Demographic patterns {#sec009}
--------------------

We found that cervical cancer was the most common type of cancer diagnosed \[n = 935 (46.7%)\] followed by breast \[n = 587(29.3%)\] and ovarian cancers \[n = 260(13%)\] ([Fig 1](#pone.0230625.g001){ref-type="fig"}). Breast cancer was most common among patients aged 35--39 and dramatically declined after the age of 50 years ([Fig 2](#pone.0230625.g002){ref-type="fig"}). In contrast, the risk of cervical cancer appeared to generally increase with age, with the risk plateauing around age 50--54 ([Fig 2](#pone.0230625.g002){ref-type="fig"}). Additionally, the number of cases of other types of malignancies (i.e. ovarian, endometrial and myometrial cancers) appeared not to increase markedly with age ([Fig 2](#pone.0230625.g002){ref-type="fig"}). More than half of the patients reported that they were from Addis Ababa: breast n = 332 (56.6%), cervix n = 506 (54.1%), and ovary n = 136 (52.3%). The Oromia and Amhara regions were the next two common regions represented, reflecting their increasing distances from the Saint Paul's Hospital Millennium Medical College ([Table 1](#pone.0230625.t001){ref-type="table"}).

![Proportional morbidity of breast and gynecological cancers among clients presenting at SPHMMC, 2014--18.\
FT&LB: Fallopian tube and Broad ligaments.](pone.0230625.g001){#pone.0230625.g001}

![Age distribution of breast and gynecological cancers presenting at SPHMMC, 2014--2018.](pone.0230625.g002){#pone.0230625.g002}

10.1371/journal.pone.0230625.t001

###### Distribution of breast and gynecological cancers presenting at SPHMMC by place of residence 2014--18.

![](pone.0230625.t001){#pone.0230625.t001g}

  Place of residence   Frequency No (%)
  -------------------- ------------------
  Addis Ababa          1098(54.8%)
  Oromia               763(38.1%)
  Amhara               126(6.3%)
  Tigrai               15(0.75)
  Total                2002(100%)

Histopathologic subtypes {#sec010}
------------------------

There were a total of 587 histologically confirmed breast cancer cases with different histologic types broadly classified as carcinoma \[n = 570 (97.1%)\], sarcoma \[n = 14 (2.4%)\] and phyllodes tumor \[n = 3 (0.5%)\]. Among the carcinoma cases, ductal carcinoma (81.6%) was the predominant subtype of cancer observed ([Table 2](#pone.0230625.t002){ref-type="table"}). Squamous cell carcinoma of the cervix was the most common type of cervical malignancy detected accounting for 90.% of all cases, while adenocarcinoma (3.85%) was the second most observed type of cervical cancer ([Table 3](#pone.0230625.t003){ref-type="table"}). For ovarian cancer cases, serous tumors were the most common histopathologic type, accounting for 37.3% of ovarian cancers. Mucinous tumors were the next most common histopathologic type accounting for 11.1% of cases ([Table 4](#pone.0230625.t004){ref-type="table"}). Among the cancers of endometrium, squamous cell carcinoma was the most common type constituting more than a quarter (27.2%) of the cases followed by adenocarcinoma which accounted for 18.4%. Stromal carcinoma and leiomyosarcoma were among the types with few cases ([Fig 3](#pone.0230625.g003){ref-type="fig"}).

![Histopathological classification of endometrial cancer, 2014--18, SPHMMC.\
SCC: Squamous cell carcinoma.](pone.0230625.g003){#pone.0230625.g003}

10.1371/journal.pone.0230625.t002

###### Histopathological classification of breast cancer, 2014--18, SPHMMC.

![](pone.0230625.t002){#pone.0230625.t002g}

  Histopathological type      Frequency (%)
  --------------------------- ---------------
  Carcinoma                   570(97.1%)
      Adenocarcinoma          7(1.2%)
      Unspecified carcinoma   40(6.81%)
      Ductal                  479(81.6%)
      Lobular                 23(3.9%)
      Mixed                   17(2.9%)
       Metaplastic            4(0.7%)
  Sarcoma                     14(2.4%)
  Phyllodes tumor             3(0.5%)
  Total                       587(100%)

10.1371/journal.pone.0230625.t003

###### Histopathological classification of cervical cancer, 2014--18, SPHMMC.

![](pone.0230625.t003){#pone.0230625.t003g}

  Histopathogic type        Frequency (%)
  ------------------------- ---------------
  Squamous cell carcinoma   844(90.3%)
  Adenocarcinoma            36(3.85%)
  Adenosquamous carcinoma   11(1.2%)
  Carcinoma, unspecified    22(2.35%)
  Others                    22(2.35%)
  Total                     935(100%)

10.1371/journal.pone.0230625.t004

###### Histopathological classification of ovarian cancer, 2014--18, SPHMMC.

![](pone.0230625.t004){#pone.0230625.t004g}

  Histopathologic type      Frequency (%)
  ------------------------- ---------------
  Serous (n = 97)           97(37.35)
      Carcinoma             45(46.4%)
      Adenocarcinoma        27(27.83)
      Cystadenocarcinoma    12(12.37)
      Papillary Carcinoma   13(13.4%)
  Mucinous(n = 29)          29(11.15)
      Carcinoma             10(34.5%)
      Adenocarcinoma        9(31%)
      Cystadenocarcinoma    10(34.5%)
  Teratoma                  22(8.46%)
  Squamous cell carcinoma   17 (6.5%)
  Carcinoma, unspecified    17(6.5%)
  Adenocarcinoma            13(5%)
  Cystadenocarcinoma        9(3.5%)
  Others                    56 (21.6%)
  Total                     260

Time trends {#sec011}
-----------

The number of breast and gynecologic cancers being treated at SPHMMC increased over the five year period from 2014--18. A slight decrement was observed in the year 2017 where 390 new cases were diagnosed. However, the number of female breast and gynecologic cases increased the following year with 554 new cases diagnosed in 2018 ([Fig 4](#pone.0230625.g004){ref-type="fig"}).

![Trend of breast and gynecologic cancers, 2014--18, SPHMMC.](pone.0230625.g004){#pone.0230625.g004}

Based on this trajectory, the number of breast and gynecologic cancers seen at SPHMMC are estimated to continue increasing over the next decade as estimated based on method of best fit (least squares) linear regression. By 2028, the numbers of new cases are expected to double from 2018, increasing from 554 new cases to 1141 new cases per year (R^2^ = 0.98).

Discussion {#sec012}
==========

Globally, gynecological malignancies are among the top causes of cancer related mortality even though the distribution and frequency is variable across regions \[[@pone.0230625.ref002], [@pone.0230625.ref003]\]. Our study demonstrates that out of total gynecological malignancies, cervical cancer was the most common with breast cancer the second most common cancer observed, accounting for more than 75% of the total malignancies observed over a five year period. These findings are similar to one previous study conducted in Tikur Anbessa Specialized Hospital, Addis Ababa \[[@pone.0230625.ref009]\], which indicated that gynecological and breast cancer were the two most common types of malignancies observed accounting for 58.86% of total cancer cases. Our findings are also similar to those from a study conducted in Pakistan \[[@pone.0230625.ref010]\] and a recent IARC report indicating that cervical cancer is the commonest gynecological malignancy in developing countries where organized screening programs do not exist \[[@pone.0230625.ref011]\]. The high number of cervical cancer cases in Ethiopia can be explained by a high rate of early marriage and a high number of live births \[[@pone.0230625.ref012]\] which might indicate early sexual commencement and possible change in partner, absence of a routine cervical cancer screening program, and low uptake of screening among high risk populations \[[@pone.0230625.ref013]\]. However, this finding is contrary to the estimates of cancer incidence in Ethiopia in 2015 using population based registry data \[[@pone.0230625.ref008]\] where breast cancer was found to be the commonest cancer followed by cervical and ovarian malignancies. This difference might be explained by the difference in sample size or by differences in prevalence by region as the former study used hospital based data collected from six regions in the country in addition to Addis Ababa cancer registry data.

Most of the tumors in our study (i.e. breast, ovarian and endometrial cancers) are most frequently diagnosed among younger women, which is similar to most studies conducted in Sub Saharan Africa \[[@pone.0230625.ref007], [@pone.0230625.ref009]\] but in contrast to findings from western population based studies \[[@pone.0230625.ref014], [@pone.0230625.ref015]\] \[[@pone.0230625.ref016]\]. This could possibly be explained by better health seeking behavior among younger women in Ethiopia where older women may not seek care for cancer. Another possible explanation could be the presence of environmental risk factors for these cancers that may have increased in recent time periods. In addition, genetic risk factors and/or the interplay of genetic and environmental or lifestyle factors may play a role. Brinton et al. \[[@pone.0230625.ref017]\] also elaborated the fact that African women may develop unique breast tumor subtypes could also be an important contributory factor to the unusual age distribution noted in Africa. Further work is needed to understand the apparent higher risk of these cancers among younger women in Ethiopia.

The fact that the incidence of cervical cancer increases in older age groups in our study is similar to others conducted in Addis Ababa \[[@pone.0230625.ref018]\] and Nigeria \[[@pone.0230625.ref019]\]. This might be due to late presentation of patients at an advanced clinical stages of the disease or not receiving or completing prescribed courses of treatment due to deficiencies in treatment availability, accessibility, and affordability as demonstrated in other similar studies \[[@pone.0230625.ref020]\]. Our data suggest that women in our study develop cervical cancer at later ages compared to European populations, where the incidence of cervical cancer begins to increase at age 20--29 years and upsurges rapidly to reach a highest level usually around age 45--49 years \[[@pone.0230625.ref021]\]. However, data from the United States Surveillance, Epidemiology and End Results (SEER) registry system in 2010 demonstrated that, even in the US, blacks are older than whites at diagnosis for cervical cancer among others which is explained to be determined by etiologic, subtype heterogeneity as well as disparities in access to care \[[@pone.0230625.ref022]\].

Our findings by histopathologic subtype were very similar to those previously reported in the literature for multiple populations worldwide. For breast cancer, we observed that ductal carcinoma was the most commonly observed histopathologic type, which is similar to the findings from other studies conducted among African women \[[@pone.0230625.ref023]--[@pone.0230625.ref025]\] and in the United states as well \[[@pone.0230625.ref026]\]. It should be noted, however, that this might be influenced by different factors including the difficulty of evaluating the prevalence of more unusual types of breast cancer, and the difficulty of determining the histopathology of advanced-stage, poorly differentiated tumors that have lost any distinguishing features, which are more common in African populations.

We have found squamous cell carcinoma of the cervix to be the most commonly observed histolopathologic type which is similar to other studies conducted in Pakistan and Bangladesh \[[@pone.0230625.ref010]\] \[[@pone.0230625.ref027]\]. The fact that this histopathologic type is pathogenically associated with Human Papilloma Virus might explain its prevalence. However, some studies indicate that adenocarcinoma, increasing and up to 20% to 25% is reported in some cases \[[@pone.0230625.ref028]\]. The same finding is observed in our study where its incidence increased from 8% in 2014 to 35% in 2018.

Epithelial, specifically serous tumor, was the predominant type of ovarian cancer in our population, similar to the findings of studies conducted in other populations \[[@pone.0230625.ref010], [@pone.0230625.ref027], [@pone.0230625.ref029]\]. Unfortunately, serous tumors are mostly high-grade serous carcinomas and are characterized by aggressive behavior, late-stage diagnosis, and low survival, contributing to the poor survival for ovarian cancer overall \[[@pone.0230625.ref030]\].

The overall incidence of breast and gynecologic cancer increased over the five year study period with a minimal downturn in the year 2017; this might have been due to the overall decrease in the number of hospital visitors due to social instability that occurred in Ethiopia during 2017. The observed increase in incidence is probably due to changes in socio demography, lifestyle or increased awareness of patients about cancer and care seeking behavior. The increasing trends in the number of breast and gynecologic cancer patients in our study area is similar to those observed across Africa \[[@pone.0230625.ref009], [@pone.0230625.ref018]\], but differs from trends in developed countries where the incidence and mortality due to cancer is decreasing\[[@pone.0230625.ref031], [@pone.0230625.ref032]\]. This difference is largely due to differences in exposures to major risk factors, detection practices like availability of diagnostic and screening services, awareness of early signs and symptoms, and availability of treatment.

To our knowledge, this study is the first to characterize female breast and gynecologic cancers in the country with respect to providing more recent trend and histopathologic information. However, our study had a few limitations. We lacked information on some important variables, including stage of the malignancy, as well as other demographic and lifestyle variables as these were not recorded in the medical records. Additionally, having data from a limited number of years makes it difficult to run most robust analysis methods for trends across time, such as joint point analysis.

Conclusion {#sec013}
==========

In conclusion, in this descriptive study we found that breast and gynecologic cancers are important public health problems among women in Addis Ababa, and that the number of patients seeking care for these cancers is increasing. Importantly, many of these cancers were more common in younger women than expected, based on studies conducted in Western populations.

General, nonspecific prevention mechanisms including change in life styles and early screening would help to minimize risk of majority of breast and gynecological cancers. However, specific measures like mastectomy may prevent breast cancer while cervical cancer can be prevented with safe sexual practices and vaccination. Therefore, there is the need to increase public awareness and consecutive practices of these factors. Government and non-governmental organizations should establish sustainable national and regional cancer screening programs and treatment centers.

Additional studies should be conducted to identify the possible risk factors for these cancers, particularly among younger women, to characterize the trends over time and to project the scope of the cancer problem expected in the future. This information will be invaluable in informing the creation of a comprehensive cancer control plan and targeted interventions for the prevention of breast and gynecologic cancers in Ethiopia.

Supporting information {#sec014}
======================
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Dear Dr Haimanot Hailu,

Thank you for submitting your revised manuscript to PLOS ONE. The revised version addresses most of the points raised during the review process in an acceptable way. However, I would like to point out one concern and question  (point 5) raised by Reviewer 2.

The comment concerned one sentence in the \"Conclusions\" part: \"Breast and gynecological cancers are largely preventable diseases\".  The reviewer wanted to get this sentence justified and offered explanations. Although your reply is generally acceptable, it did not make the sentence more clear. Although breast cancer is generally considered to be largely influenced by the environmental factors, diet, life style, reproductive history etc,, there are no specific means to prevent the disease at the individual level. The same is true in case of ovarian cancer and other gynecological cancers. On the contrary, cervical cancer, besides the mode of sexual behaviour, can be be prevented to a great extent by vaccination. Therefore I would ask you to reconsider this sentence and to specify how and to which extent breast cancer and other gynecological cancers can be prevented.

We would appreciate receiving your revised manuscript by March 9, 2020. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Pirkko L. Härkönen, M.D., Ph.D.

Academic Editor

PLOS ONE

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Dr. Hailu,

We are pleased to inform you that your manuscript revised as reported has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Pirkko L. Härkönen, M.D., Ph.D.

Academic Editor
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Dear Dr. Hailu:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff
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